Safety and Efficacy Evaluation of 4th Generation Safety-engineered CAR T Cells Targeting Sarcomas
Trial statusRecruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age1-75
SponsorShenzhen Geno-Immune Medical Institute
About this trial
The aim of this clinical trial is to assess the feasibility, safety and efficacy of CAR T cells immunotherapy in patients who have sarcoma that is relapsed or late staged. Another goal of the study is to assess the safety and efficacy of the therapy that combines CAR T cells and IgT cells to treat sarcoma.
Eligibility criteria
Qualifiers
Stage Ⅲ，Ⅳ sarcoma patients or recurrent sarcoma patients;
Age: ≥ 18 and ≤65 years of age at the time of enrollment;
At least 4 weeks since any chemotherapy or radiotherapy and at least 1 week since immunosuppressive therapy such as using steroid hormone before enrollment;
Side effects of chemotherapy have been well managed;
Disqualifiers
The disease is progresseing rapidly;
The patient is receiving therapy of other new drugs;
Evidence of tumor potentially causing airway obstruction;
Epilepsy history or other CNS diseases;
Trial design
Treatments tested in this trial
- Sarcoma-specific CAR-T cells
Treatment groups
20 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov